Investor Relations

Boston Therapeutics Requests an IND Meeting With the FDA for PAZ320 to Reduce Postprandial Hyperglycemia in Type 2 Diabetes

Download PDF

MANCHESTER, NH -- (Marketwired) -- 04/11/13 -- Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a pharmaceutical company developing and commercializing complex carbohydrate-based drugs to treat diabetes and inflammatory diseases, has requested an Investigational New Drug (IND) application meeting with the U.S. Food and Drug Administration (FDA). The IND application will support a proposed indication of PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose (PPG) or post-meal blood sugar, for treatment of patients with type 2 diabetes. PAZ320 is the first compound in a new class of therapies for PPG, called Carbohydrate Hydrolyzing Enzyme Inhibitors (CHEI).

"This IND meeting will be another important milestone in the clinical development program of PAZ320 for the treatment of diabetes," said David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics. "Our leadership position in complex carbohydrate chemistry enables us to bring new treatment options to a disease that is reaching epidemic proportions. PAZ320 as a new class of anti-diabetes drug may be the key to prevention or managing type 2 diabetes."

About PAZ320

PAZ320 is a single chemical structure, non-systemic (in the intestine), chewable carbohydrate hydrolyzing enzyme inhibitor (CHEI) designed to reduce the elevation of post-prandial glucose (PPG), or after-meal blood sugar. Patients with type 2 diabetes who responded in the clinical study conducted at Dartmouth Medical Center reported a 40 percent reduction in PPG and no Serious Adverse Events.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is a leader in the field of complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including PAZ320, a non-systemic chewable therapeutic compound designed to reduce the elevation of post-prandial glucose (PPG) or post-meal blood sugar, and IPOXYN™, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at

Forward Looking Statements

Any statements in this news release about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.


Boston Therapeutics, Inc.
Anthony Squeglia
Director of Strategic Planning
Phone: 603-935-9799

Source: Boston Therapeutics